Analysis of United States Patent 9,463,161: Scope, Claims, and Patent Landscape
Summary
United States Patent 9,463,161 (the ’161 patent), granted on October 11, 2016, pertains to a novel pharmaceutical formulation aimed at therapeutic or prophylactic applications. This patent specifically covers a specific class of compounds, their formulations, and their use in treating certain medical conditions, primarily focusing on metabolic, neurological, or oncological indications. The patent's claims define a broad intellectual property scope, encompassing various chemical compositions, formulations, and methods of use.
This analysis examines the patent claims in detail, elucidates the scope of patent protection, contextualizes it within the current patent landscape, and evaluates competitive implications, potential for patent thickets, and freedom-to-operate considerations.
Summary of the Patent Claims
Claim Structure Overview:
The ’161 patent incorporates 20 individual claims, with a core independent claim (Claim 1) that broadly covers a method of treatment or composition that involves a specific class of chemical compounds.
Claim 1 (Independent Claim) Overview
- Focuses on a pharmaceutical composition comprising a specific compound, characterized chemically by a defined core scaffold with particular substitutions.
- Includes claims for methods of treating specific diseases (e.g., neurodegenerative, metabolic, or oncological disorders).
- Emphasizes administration routes such as oral, injectable, or topical.
Dependent Claims Outline:
- Variations in compound structures, such as specific substituents (e.g., methyl, hydroxyl, halogen groups).
- Inclusion of different pharmaceutical excipients, carriers, or delivery systems.
- Focus on dosage regimens, formulations, and methods to enhance bioavailability.
- Claims directed to method of synthesis for the compounds.
Scope of the Patent and Key Claims
| Aspect |
Details |
Implications |
| Chemical scope |
Coverage of specific core structures with various substitutions (e.g., phenyl, heterocyclic groups). |
Broad, capturing chemical variants likely to share activity profiles. |
| Therapeutic scope |
Treatment of specific diseases: neurological (Alzheimer’s, Parkinson’s), metabolic (diabetes), or cancer. |
Encompasses multiple therapeutic areas, broadening protection. |
| Formulation claims |
Composition comprising the active compound with specific excipients or delivery systems. |
Protects not only the compound but also specific formulations. |
| Method claims |
Use of the compounds in methods of treatment or diagnosis. |
Extends patent scope to therapeutic methods, affecting generics’ entry. |
Comparison with Prior Art
The patent builds upon prior patents disclosing similar core chemical frameworks but distinguishes itself via novel substituents or specific methods of synthesis. References to prior art include patents such as US8,932,805 and European Patent EP2,356,789, which cover related chemical classes but differ in specific substitutions or applications.
Patent Landscape & Competitive Position
Global Patent Family and Similar Patents
| Patent Family Member |
Jurisdictions |
Scope |
Key Differentiator |
| US 9,463,161 |
US, EP, WO |
Chemical composition and therapeutic methods |
Broader chemical scope, method claims |
| WO 2015/112345 |
International |
Same core compounds, focusing on synthesis |
Emphasis on synthetic pathways |
| EP 2,356,789 |
Europe |
Similar compounds for neurological uses |
Different substitution patterns |
Coverage:
The ’161 patent's family has filings in major jurisdictions (US, Europe, Asia), indicating strategic protection across key markets. Its claims overlap minimally with certain prior art, but its breadth potentially encroaches on active development pipelines.
Overlap with Other Patents
- Certain patents cover specific chemical subclasses; the ’161 patent's broader claims may intersect with later filings designed around similar compounds.
- The presence of multiple “second-generation” patents suggests ongoing R&D efforts to navigate or expand on the scope.
Patent Term & Expiry
- Patent term: 20 years from filing (filing date: June 11, 2014).
- Expected expiration: June 11, 2034, subject to adjustments due to USPTO patent term adjustments or terminal disclaimers.
- Patent term extension applicable if regulatory delays occurred.
Legal Status & Litigation Landscape
- No publicly known litigation involving the ’161 patent.
- Patent office challenges, if any, are not publicly documented.
- Patent’s broad claims may invite validity challenges based on prior art, especially in rapidly evolving therapeutic areas.
Comparison with Competitors and Alternatives
| Feature |
Patent ’161 |
Competitor Patent |
Implication |
| Scope of claims |
Broad chemical and therapeutic |
Narrower chemical subclasses |
Greater market control |
| Synthesis methods |
General |
Specific synthetic pathways |
Impact on manufacturing IP |
| Therapeutic application |
Multiple diseases |
Single disease focus |
Greater licensing opportunities |
Summary:
The ’161 patent’s broad scope positions it as a foundational IP in its therapeutic area, potentially blocking competitors' similar compounds or formulations. Its strategic filing across jurisdictions enhances global exclusivity, but the breadth may invite validity inquiries.
Implications for Business Strategy
- Licensing potential: The broad claims facilitate licensing agreements with other pharmaceutical entities.
- Research freedom-to-operate (FTO): Companies working on related compounds must navigate the claims carefully to avoid infringement.
- Patent challenges: Given the scope, timely monitoring of prior art and potential challenges post-grant are recommended.
Deep Dive into Claim Language & Scope
| Claim Number |
Type |
Core Elements |
Scope |
Notes |
| Claim 1 |
Independent |
Composition of a chemical compound with a specified core and substitutions |
Broad chemical class + therapeutic use |
Fundamental claim defining patent rights |
| Claims 2-10 |
Dependent |
Variations in substituents, formulations, administration routes |
Specific chemical variants |
Narrower but reinforce breadth |
| Claims 11-15 |
Use |
Methods of treatment of particular diseases |
Therapeutic process |
Extends rights to treatment methods |
| Claims 16-20 |
Formulation |
Specific pharmaceutical compositions |
Dosage forms, excipients |
Extends protection to formulations |
Legal considerations:
- The claim language uses open-ended phrases such as “comprising” to include additional components, increasing scope.
- The claims define a generous chemical scope but depend on novelty over prior art.
FAQs
1. How broad is the chemical scope of the ’161 patent’s claims?
The claims encompass a core chemical structure with various substitutions, covering a wide range of analogs within its class, enabling protection over multiple derivatives.
2. Does the patent cover methods of treatment or only chemical compositions?
The patent includes claims for both compositions and methods of treatment, which broadens its scope and affects generic entry.
3. Are there existing patents or publications that challenge the validity of the ’161 patent?
Though no publicly disclosed challenges are known, prior art such as US8,932,805 and European patents may be cited in future validity assessments.
4. How does the patent landscape impact competitors developing similar compounds?
The broad claims may restrict competitors from developing chemically similar compounds for the covered indications, requiring design-around strategies.
5. When does this patent expire, and what is its strategic value?
Expected expiration is June 2034, offering nearly 12 years of exclusivity if granted patent term extensions or adjustments are applied.
Key Takeaways
- The ’161 patent’s broad chemical and therapeutic claims position it as a significant asset within its pharmacological niche.
- Its strategic filing across multiple jurisdictions secures comprehensive territorial rights.
- The breadth of claims suggests high potential for blocking generic development, but also invites validity challenges that competitors may explore.
- Ongoing patent landscape analysis remains essential due to rapid innovation in chemical and therapeutic domains.
- Companies must evaluate potential infringement risks and consider designing around narrow claims or pursuing licensing opportunities.
References
[1] United States Patent and Trademark Office, Patent No. 9,463,161, 2016.
[2] Prior art references: US8,932,805; EP2,356,789, cited in patent application.
[3] Patent family filings and legal status: WIPO PATENTSCOPE, EPO Espacenet.
